Home » Stocks » Lumos Pharma

Lumos Pharma, Inc. (LUMO)

Stock Price: $15.15 USD 0.81 (5.65%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 125.64M
Revenue (ttm) 851,000
Net Income (ttm) -32.61M
Shares Out 8.29M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $15.15
Previous Close $14.34
Change ($) 0.81
Change (%) 5.65%
Day's Open 14.25
Day's Range 14.24 - 15.16
Day's Volume 32,126
52-Week Range 6.74 - 32.40

More Stats

Market Cap 125.64M
Enterprise Value 40.91M
Earnings Date (est) Aug 13, 2020
Ex-Dividend Date n/a
Shares Outstanding 8.29M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -11.84
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 224,845
Short Ratio 6.80
Short % of Float 3.91%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 147.63
PB Ratio 0.96
Revenue 851,000
Operating Income -39.69M
Net Income -32.61M
Free Cash Flow -25.93M
Net Cash 84.73M
Net Cash / Share 10.22
Gross Margin n/a
Operating Margin -4,663.34%
Profit Margin -3,908.80%
FCF Margin -3,047.24%
ROA n/a
ROE n/a
ROIC -244.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$25.50*
(68.32% upside)
Low
18.0
Current: $15.15
High
33.0
Target: 25.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.9412.4728.7135.7768.501731.091.691.872.08
Revenue Growth-92.5%-56.55%-19.73%-47.78%-60.31%15690.67%-35.21%-9.88%-9.96%-
Gross Profit0.9412.4728.7135.7768.501731.091.691.872.08
Operating Income-45.13-62.44-72.88-90.76-33.60118-31.14-23.26-18.06-16.66
Net Income-42.99-53.60-71.95-85.16-40.3896.02-31.18-23.32-18.09-16.21
Shares Outstanding4.144.133.483.223.183.092.812.310.670.37
Earnings Per Share-10.35-12.96-20.70-26.46-12.6927.81-11.07-10.08-26.82-43.56
Operating Cash Flow-30.21-37.94-48.28-65.95-24.09109-25.82-20.47-12.95-13.27
Capital Expenditures0.080.120.21-2.25-4.00-1.70-1.39-1.27-0.28-2.93
Free Cash Flow-30.13-37.82-48.07-68.19-28.08107-27.20-21.74-13.23-16.20
Cash & Equivalents4.9512115913119820361.5421.7441.9812.84
Total Debt0.380.100.330.911.8314.101.221.387.167.29
Net Cash / Debt4.5712115813119618960.3220.3634.825.55
Assets5.5313118117521923170.5629.4348.3820.08
Liabilities1.4515.8029.1445.2822.7734.2912.2311.5011.6110.35
Book Value-59.4611515212919619758.3317.9336.77-54.96
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lumos Pharma, Inc.
Country United States
Employees 27
CEO Richard J. Hawkins

Stock Information

Ticker Symbol LUMO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LUMO

Description

Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.